id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-305793-xmkiqgbn	Giovannoni, Gavin	Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19	2020-04-18		.txt	text/plain	937	62	47	It is also assumed that people who are immunocompromised, for example, patients with multiple sclerosis (MS) on immunosuppressive disease-modifying therapies (DMTs) are also at increased risk of severe COVID-19. It is therefore very reassuring to read in this issue a case report of a patient with primary progressive MS previously treated with ocrelizumab, an anti-CD20 B-cell depleting monoclonal antibody, who developed uncomplicated COVID-19 (Novi G, Mikulska M, Briano F, Toscanini F, Tazza F, Uccelli A, Inglese M, 2020) . This case and online reports support the hypothesis that immunosuppression, or at the least moderate immunosuppression associated with MS DMTs, may protect against the development of severe COVID-19 infection. However, there are always rare exceptions to the rule; for example, a single case report of fulminant hepatitis associated with an unusual echovirus-25 infection in a patient on ocrelizumab therapy (Nicolini et al., 2019; Novi G, Mikulska M, Briano F, Toscanini F, Tazza F, Uccelli A, Inglese M, 2020) .	./cache/cord-305793-xmkiqgbn.txt	./txt/cord-305793-xmkiqgbn.txt